Skip to main content

Ollin Biosciences to Participate in Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced management will participate in two upcoming investor conferences:

2026 Jefferies Global Healthcare Conference
1x1 Meetings: Tuesday, June 2
New York, NY

Evercore 2026 Emerging Private Biotech Conference
Ophthalmology Panel: Wednesday, June 24, 8:50 a.m. ET
Newport, RI

About Ollin Biosciences

Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.68
+5.57 (2.38%)
AAPL  296.03
+1.73 (0.59%)
AMD  511.12
-8.73 (-1.68%)
BAC  57.57
-0.34 (-0.59%)
GOOG  348.31
+2.23 (0.64%)
META  555.96
-6.25 (-1.11%)
MSFT  371.00
-2.94 (-0.79%)
NVDA  198.24
-1.80 (-0.90%)
ORCL  155.72
-9.44 (-5.72%)
TSLA  375.69
-5.93 (-1.55%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.